Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > News > Abraxis Fires AstraZeneca, Gets Fired Up

November 26th, 2008

Abraxis Fires AstraZeneca, Gets Fired Up

Abstract:
Buoyed by deep pockets filled with cash after it separated from its generic drug business, Abraxis Bioscience (Nasdaq: ABII) is moving into the deep end with the big boys. The platform drugmaker decided to end its marketing agreement with AstraZeneca (NYSE: AZN) and sell its cancer drug Abraxane by itself.

It'll cost the company $268 million to get out of the partnership, but the timing seems right; Abraxane has been competing well against the other taxanes -- Bristol-Myers Squibb's (NYSE: BMY) Taxol and Sanofi-Aventis' (NYSE: SNY) Taxotere -- in the metastatic breast cancer market and is poised for growth into other cancers. It also has compounds in its pipeline that could be sold using the same drug delivery technology, so building out now isn't unreasonable.

The agreement still needs to be approved by Abraxis' board, but a thumbs-up seems likely, because if the company stays with AstraZeneca, it will have to start paying a commission of 50% -- more than double the 22% commission that AstraZeneca currently gets.

Source:
fool.com

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

New class of protein misfolding simulated in high definition: Evidence for recently identified and long-lasting type of protein misfolding bolstered by atomic-scale simulations and new experiments August 8th, 2025

Sensors innovations for smart lithium-based batteries: advancements, opportunities, and potential challenges August 8th, 2025

Deciphering local microstrain-induced optimization of asymmetric Fe single atomic sites for efficient oxygen reduction August 8th, 2025

Lab to industry: InSe wafer-scale breakthrough for future electronics August 8th, 2025

Investments/IPO's/Splits

Daikin Industries becomes OCSiAl shareholder July 27th, 2021

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

Nanomedicine

New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025

New imaging approach transforms study of bacterial biofilms August 8th, 2025

Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025

Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025

Announcements

Sensors innovations for smart lithium-based batteries: advancements, opportunities, and potential challenges August 8th, 2025

Deciphering local microstrain-induced optimization of asymmetric Fe single atomic sites for efficient oxygen reduction August 8th, 2025

Japan launches fully domestically produced quantum computer: Expo visitors to experience quantum computing firsthand August 8th, 2025

ICFO researchers overcome long-standing bottleneck in single photon detection with twisted 2D materials August 8th, 2025

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project